Klaria’s subsidiary Cannabis Delivery Sciences (CDS) signs strategic collaboration agreement with Pure Jamaican Limited
Cannabis Delivery Sciences (CDS), a daughter company of Klaria Pharma AB listed on NASDAQ First North (KLAR.ST) today announced that it has entered into an exclusive strategic partnership with Pure Jamaican Limited. Pure Jamaican is a company developing highly modern cultivation of proprietary cannabis strains as well as large-scale pharmaceutical cannabis extraction and Active Pharmaceutical Ingredient (API) production capabilities in Jamaica.
The aims for CDS in the collaboration are to conduct R&D, develop products, manufacture and distribute internationally medical grade cannabinoid-loaded Alginate Films (“Cannabis Alginate Film”) by:
- Building out manufacturing and production of medical grade cannabinoid Cannabis Alginate Films;
- Creating and suppling a scalable international supply chain of Cannabis Alginate Film;
- Enable the development and sales of Cannabis Alginate Films with exclusivity in the Latin America and the Caribbean region (“LAC Region” which is defined as Mexico, Central America, South America and the Caribbean);
- Produce medical grade products in Jamaica for testing and clinical trials
With this partnership Cannabis Delivery Sciences has gained all the capabilities and competencies of a fully integrated medical cannabis company. As an example of the depth of the collaboration and its transformative potential for CDS, the company will now own a production line in one of Pure Jamaican’s cannabis product manufacturing facilities.
Scott de Mercado, head of Business Development for Cannabis Delivery Sciences, said “The vision of CDS is to make the Cannabis Films the de-facto product for medical cannabis worldwide. This partnership brings us closer to that vision in Latin America and the Caribbean. These are large markets with significant commercial potential, for example Mexico is the largest legal medical cannabis market in the world.”
Fredrik Hubinette, Chairman of Klaria Pharma, which is the mother company of CDS, continued “We now have the required capabilities and competencies of a fully integrated medicinal cannabis company. Our delivery technology offers a precise dose with high bioavailability and a rapid onset of action. Together with Pure Jamaican’s proprietary strains of the highest quality cannabis and their pharmaceutical manufacturing expertise, we will create a new and superior category of medical cannabis products with unique and valuable benefits for patients across the world.”
About Cannabis Delivery Sciences– CDS is a cannabis focused drug delivery company with a patent protected, proprietary technology. We are making oral films loaded with cannabinoids that deliver rapid and precise dose of cannabis. The films are based on alginate polymers extracted from the North Sea brown algae (Kelp) harvested from sustainable Kelp forests. CDS is a daughter company of Klaria Pharma AB which owns the Alginate Film Technology patent estate.
For more information see: https://cannabisdeliverysciences.com/